IPO Digest — June 16, 2026: Quiet Debuts, Active Hong Kong Pipeline

June 16 at a glance

The June 16 IPO tape was quiet on actual debuts: the A-share calendar showed no new-share subscription or listing item, while Eastmoney's Hong Kong IPO calendar showed no new HK listing for the day. The action was instead in payments and Hong Kong pipeline updates: two A-share IPOs moved to allotment-payment day, and five HKEX candidates either filed or advanced their application files as of the evening Hong Kong session. 1 2

Market	June 16 verified event	What changed	Immediate next step
A-share	0 new subscriptions; 0 new listings	Huike Co. (001399) and Zhenbao Technology (688797) had winning-number/payment events; Jihechang (920193) is scheduled for June 17 subscription at RMB 8.52. 1	Watch June 17 BSE subscription flow and later listing dates for Huike/Zhenbao.
Hong Kong	0 new listings	HKEX calendar showed no debut; pipeline activity came from filings and post-hearing materials rather than first-day trading. 2	Track offer terms, pricing ranges, and hearing updates.

June 16 IPO calendar snapshot — Self-made chart summarizing the June 16 monitoring snapshot, based on Eastmoney's A-share and Hong Kong IPO calendars plus the verified Hong Kong pipeline sources cited below. 1 2

Status labeling for this issue: all Hong Kong names below are in the "pricing not yet confirmed" bucket unless otherwise stated. None of the entries below had first-day close data on June 16.

Hong Kong pipeline: filings and hearing updates

Company	Market / status on June 16	Sponsor(s)	Core business	Metric worth noting	Watchpoint
Taotao Vehicles (301345.SZ)	Third submission to HKEX Main Board	CITIC Securities	Outdoor recreation and electric mobility products, including low-speed electric vehicles, electric two-wheelers and powersports vehicles. 3	Prospectus-based media summary says Taotao ranked No. 1 globally in the low-speed electric vehicle industry by 2025 revenue, with about 10.9% share; 2025 revenue was about RMB 3.941B and profit about RMB 816M. 3	A+H valuation and U.S. exposure: more than 97% of 2025 revenue came from overseas markets, with the U.S. the largest export destination. 3
Sifang Automation (601126.SH)	H-share application to HKEX Main Board	Huatai International	New power-system solutions, protection and automation, smart O&M, power electronics, primary-secondary integration and energy-storage systems. 4	Frost & Sullivan data cited in the filing summary puts Sifang at No. 2 in China's protection and automation solutions market in 2025, with a 10.3% share. 5	The A+H thesis depends on whether overseas capital gives a premium for grid automation, AI data-center power infrastructure and new-energy system exposure.
Baige Online	Post-hearing information pack / passed HKEX hearing	CMBC Capital and BOCI Asia	Technology-enabled insurance intermediary services: scenario insurance distribution, precision marketing, digital solutions and TPA services. 6	A separate Eastmoney analysis shows revenue rising from RMB 660M in 2023 to RMB 1.227B in 2025, while policies sold fell from 1.968B to 494M over the same period. 7	Quality of growth: investors should separate commission revenue growth from the sharp drop in policy volume, especially in travel-scenario products.
Shanghai Junsai Bio-B	Re-submitted HKEX Main Board application	CITIC Securities	Cell-therapy biotech focused on solid tumors; core candidate GC101 is a TIL therapy for advanced melanoma. 8	The company is still pre-revenue; 2024 and 2025 losses were about RMB 164M and RMB 233M, and 2025 R&D cost was about RMB 115M. GC101 is expected to submit a BLA in September 2026. 8	This is a binary clinical/regulatory watch: the September BLA target matters more than near-term revenue multiples.
Savewo Group	Submitted HKEX GEM application	Baihui Capital	Hong Kong personal protection and healthcare products manufacturer/distributor, led by SAVEWO® disposable masks and related healthcare products. 9	FY2026 revenue was HKD 75.543M and profit was HKD 16.781M; the company ranked No. 1 in Hong Kong's mask and respirator market by revenue with about 14.1% share. 9	GEM liquidity and post-pandemic demand normalization are the key filters; the market-share headline needs to be read against a smaller mask-market baseline.

HKEX pipeline mix by company type — Self-made chart grouping the five June 16 Hong Kong pipeline candidates; count is by company, not by planned proceeds. 3 4 6 8 9

What to track next

A+H pipeline is widening, but not all A+H stories rhyme. Taotao is an export-driven consumer/mobility manufacturer; Sifang is a grid-automation and power-infrastructure supplier. Both are already A-share listed, but their Hong Kong investor base will likely price very different risks: U.S. trade exposure for Taotao, and grid/data-center capex durability for Sifang. 3 5
Baige Online is the day's closest-to-market Hong Kong name. A post-hearing information pack normally means the issuer has moved beyond the application-only stage, but the more important diligence question is whether revenue growth can offset policy-volume compression. 6 7
Junsai Bio-B is a timing story. With no product sales and a September 2026 BLA target for GC101, investors will be underwriting clinical/regulatory probability, cash runway and the scarcity value of its TIL platform rather than conventional earnings. 8
A-share trading catalysts resume quickly. June 16 had no A-share new subscription or listing in the captured calendar, but Jihechang (920193) is scheduled for June 17 subscription, keeping the BSE small-cap IPO tape active. 1

This digest is for market monitoring only and is not investment advice. Figures are as reported in the cited sources available by the June 16 evening publication window; offer sizes and valuation metrics remain unavailable for the unpriced Hong Kong applications above.